Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Melanoma immunotherapy.

Literature DB >> 24651672

Melanoma immunotherapy.

Martina Sanlorenzo¹, Igor Vujic², Christian Posch², Akshay Dajee³, Adam Yen³, Sarasa Kim³, Michelle Ashworth³, Michael D Rosenblum³, Alain Algazi³, Simona Osella-Abate⁴, Pietro Quaglino⁴, Adil Daud³, Susanna Ortiz-Urda³.

Abstract

Immunotherapy is a cornerstone in the treatment of melanoma, and is intended to modulate the host immunity against the tumor. Immunotherapy can be used in an adjuvant setting, after complete surgical excision in patients with a high risk of disease relapse and as a treatment in advanced (unresectable or metastatic) stages. Development of novel therapeutic approaches and the optimization of existing therapies hold a great promise in the field of melanoma therapy research. Different clinical trials are ongoing, and immunotherapy is showing the ability to confirm durable clinical benefits in selected groups of melanoma patients. The aim of this review is to summarize different types of immunotherapy agents, as well as to discuss different strategies, complementary regimens, and possible biomarkers of response to the treatment.

Entities: Disease Species

Keywords: CTLA-4; PD-1; anti-PD-1; immunoprofiling; interferons; interleukins; ipilimumab

Mesh：

Substances：

Year: 2014 PMID： 24651672 PMCID： PMC4049781 DOI： 10.4161/cbt.28555

Source DB: PubMed Journal: Cancer Biol Ther ISSN： 1538-4047 Impact factor: 4.742

73 in total

1. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.

Authors: S A Rosenberg; Y Zhai; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; C A Seipp; J H Einhorn; B Roberts; D E White
Journal: J Natl Cancer Inst Date: 1998-12-16 Impact factor: 13.506

2. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.

Authors: Laszlo G Radvanyi; Chantale Bernatchez; Minying Zhang; Patricia S Fox; Priscilla Miller; Jessica Chacon; Richard Wu; Gregory Lizee; Sandy Mahoney; Gladys Alvarado; Michelle Glass; Valen E Johnson; John D McMannis; Elizabeth Shpall; Victor Prieto; Nicholas Papadopoulos; Kevin Kim; Jade Homsi; Agop Bedikian; Wen-Jen Hwu; Sapna Patel; Merrick I Ross; Jeffrey E Lee; Jeffrey E Gershenwald; Anthony Lucci; Richard Royal; Janice N Cormier; Michael A Davies; Rahmatu Mansaray; Orenthial J Fulbright; Christopher Toth; Renjith Ramachandran; Seth Wardell; Audrey Gonzalez; Patrick Hwu
Journal: Clin Cancer Res Date: 2012-10-02 Impact factor: 12.531

3. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Authors: Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé
Journal: Lancet Oncol Date: 2009-12-08 Impact factor: 41.316

4. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Authors: Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; Steven A Rosenberg
Journal: Clin Cancer Res Date: 2007-11-02 Impact factor: 12.531

5. CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors.

Authors: Kavita V Shah; Andy J Chien; Cassian Yee; Randall T Moon
Journal: J Invest Dermatol Date: 2008-06-19 Impact factor: 8.551

Review 6. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections.

Authors: Tsvetelina Pentcheva-Hoang; Emily Corse; James P Allison
Journal: Immunol Rev Date: 2009-05 Impact factor: 12.988

7. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.

Authors: Howard L Kaufman; John M Kirkwood; F Stephen Hodi; Sanjiv Agarwala; Thomas Amatruda; Steven D Bines; Joseph I Clark; Brendan Curti; Marc S Ernstoff; Thomas Gajewski; Rene Gonzalez; Laura Jane Hyde; David Lawson; Michael Lotze; Jose Lutzky; Kim Margolin; David F McDermott; Donald Morton; Anna Pavlick; Jon M Richards; William Sharfman; Vernon K Sondak; Jeffrey Sosman; Susan Steel; Ahmad Tarhini; John A Thompson; Jill Titze; Walter Urba; Richard White; Michael B Atkins
Journal: Nat Rev Clin Oncol Date: 2013-08-27 Impact factor: 66.675

8. Nivolumab plus ipilimumab in advanced melanoma.

Authors: Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal: N Engl J Med Date: 2013-06-02 Impact factor: 91.245

9. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.

Authors: Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas C Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; Steven A Rosenberg; Nicholas P Restifo
Journal: J Exp Med Date: 2005-10-03 Impact factor: 14.307

10. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment.

Authors: Paolo A Ascierto; Mariaelena Capone; Walter J Urba; Carlo B Bifulco; Gerardo Botti; Alessandro Lugli; Francesco M Marincola; Gennaro Ciliberto; Jérôme Galon; Bernard A Fox
Journal: J Transl Med Date: 2013-03-03 Impact factor: 5.531

20 in total

1. Antiproliferative and apoptotic effects of caffeic acid on SK-Mel-28 human melanoma cancer cells.

Authors: Luana Paula Pelinson; Charles Elias Assmann; Taís Vidal Palma; Ivana Beatrice Mânica da Cruz; Micheli Mainardi Pillat; Aline Mânica; Naiara Stefanello; Grazielle Castagna Cezimbra Weis; Audrei de Oliveira Alves; Cinthia Melazzo de Andrade; Henning Ulrich; Vera Maria Melchiors Morsch; Maria Rosa Chitolina Schetinger; Margarete Dulce Bagatini
Journal: Mol Biol Rep Date: 2019-02-04 Impact factor: 2.316

2. Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies.

Authors: Andrew Kwong; Martina Sanlorenzo; Klemens Rappersberger; Igor Vujic
Journal: Wien Med Wochenschr Date: 2017-01-13

Review 3. CT, MRI and PET/CT features of abdominal manifestations of cutaneous melanoma: a review of current concepts in the era of tumor-specific therapies.

Authors: Maxime Barat; Sarah Guegan-Bart; Anne-Ségolène Cottereau; Enora Guillo; Christine Hoeffel; Maximilien Barret; Sébastien Gaujoux; Anthony Dohan; Philippe Soyer
Journal: Abdom Radiol (NY) Date: 2020-11-02

4. Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area.

Authors: Gregory R Stroh; Tobias Peikert; Patricio Escalante
Journal: Cancer Immunol Immunother Date: 2021-03-26 Impact factor: 6.968

Review 5. Opportunities and obstacles for the melanoma immunotherapy using T cell and chimeric antigen receptor T (CAR-T) applications: a literature review.

Authors: Maryam Bahmanyar; Mohammad Kazem Vakil; Ghaidaa Raheem Lateef Al-Awsi; Seyed Amin Kouhpayeh; Hosein Mansoori; Yaser Mansoori; Afsaneh Salahi; Ghasem Nikfar; Alireza Tavassoli; Esmaeil Behmard; Ali Moravej; Abdolmajid Ghasemian
Journal: Mol Biol Rep Date: 2022-06-18 Impact factor: 2.316

6. TLR agonist rMBP-NAP inhibits B16 melanoma tumor growth via induction of DCs maturation and T-cells cytotoxic response.

Authors: Jiaojiao Liu; Cong Ding; Xiaolong Wang; Lu Yang; Xin Liu; Qiaozhen Kang
Journal: Cytotechnology Date: 2022-07-02 Impact factor: 2.040